Associated Genetic Biomarkers
NCI Definition: A chronic, recurrent cutaneous disorder characterized by the presence of spontaneously regressing papules. The papules are composed of an atypical lymphocytic infiltrate that contains anaplastic CD30-positive T-cells, which are found in type A and diffuse large cell type (type C) lymphomatoid papulosis. In a small number of cases, of type B, the lymphocytic infiltrate is composed of small, cerebriform-like lymphocytes that are often negative for CD30. The majority of cases follow a benign clinical course, but some cases are clonal and may progress to lymphoma. Treatment options include low dose methotrexate and psoralen/UVA (PUVA). 
There are 3 clinical trials for lymphomatoid papulosis, of which 3 are open and 0 are completed or closed. Of the trials that contain lymphomatoid papulosis as an inclusion criterion, 1 is phase 1 (1 open) and 2 are phase 2 (2 open).
TNFRSF8 is the most frequent gene inclusion criterion for lymphomatoid papulosis clinical trials .
Brentuximab vedotin, autologous ccr4-cd30car-cd28-cd3zeta-expressing t-lymphocytes, and autologous cd30car-cd28-cd3zeta-expressing t-lymphocytes are the most common interventions in lymphomatoid papulosis clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.